AstraZeneca in the UK
A global pharmaceutical company with a major UK presence. Our purpose is to push the boundaries of science to deliver life-changing medicines. The best way we can help patients is to be science-led and share this passion with the scientific, healthcare and business communities of the UK.
Our contribution to the UK
Employment
We employ 7,897 employees across five sites in the UK and support around 41,000 other jobs.
Investment in the business
We are continually investing in our UK business and have made a number of significant investments including: a purpose-built R&D centre, corporate HQ in Cambridge, and an investment of £120 million in a new facility at our manufacturing centre in Macclesfield, Cheshire.
Innovation
We continue to be an integral part of the scientific community in the UK, employing more than 2,600 employees focused on high value R&D activities. This is backed up by significant R&D investment, including the opening of our new Global R&D Centre in Cambridge in 2021.
Our UK sites
Scroll through the locations below to find out more about our sites in the UK.
Who we work with
The NHS
AstraZeneca’s relationship with the NHS is at the centre of our UK Marketing Company activities. The NHS is the primary customer for AstraZeneca medicines in the UK and we engage with NHS staff on many levels on a daily basis.
Government and policy makers
Working with the UK Government, policy makers and regulatory bodies is essential to ensure that patients in the UK can access innovative medicines when they need them.
Patient groups
In the UK, we have a long-standing history of working with patient groups helping people in specific disease areas.
UK Healthcare Professionals
The NHS is the primary customer for AstraZeneca medicines in the UK and we engage with NHS staff on many levels on a daily basis.
Grants
AstraZeneca UK aims to support local innovation and best practice that improves patient care in Respiratory, Immunology, Cardiovascular, Metabolic, Renal and Oncology therapy areas. Grants are a reactive provision of monetary support by AstraZeneca to an approved requesting organisation for the purposes of achieving a specific defined outcome. Grants may be awarded to Healthcare Organisations, Patient Organisations, or Charities involved in patient support. The Grants process does not accept Externally Sponsored Research or Product Donation requests (they are reviewed via alternative processes).
Once you have submitted your grant application, your request will be reviewed by committee. The committee will be looking for a clear alignment to at least one of AstraZeneca’s Medical Missions for practice change (see below) AND clear advancement in UK clinical practice (with potential to scale UK-wide) AND/OR impact on reducing health inequalities aligned to AstraZeneca’s Medical Missions.
Please click this link and complete a request in the Cybergrants Tool
- The total review time can be up to 10-12 weeks, therefore please allow sufficient time to apply before the proposed project/activity start date. We will contact you by email with the outcome.
- Should your application be successful, a member of the AstraZeneca UK Medical and Scientific Affairs team will periodically be reaching out to you to confirm progress of the project at appropriate timely intervals.
Grants are provided by AstraZeneca without intent or agreement for AstraZeneca to receive any benefit in exchange (a mere display of the AstraZeneca logo or name is not considered a benefit).
AstraZeneca UK’s Medical Missions for practice change:
- Zero Tolerance for Asthma Attacks - all patients deserve access to anti-inflammatory medicines from the start
- Eliminate chronic oral corticosteroids (OCS) - accelerate access to precision medicine, reduce OCS use by 90%
- Early biology-based treatment of Chronic Obstructive Pulmonary Disease - early diagnosis, treatment, prevention of decline, cardiovascular complications and premature death
- Prevent onset of cardiorenal disease in Type 2 Diabetes - treat beyond Haemoglobin A1C (HbA1C) to prevent onset of Heart Failure, Chronic Kidney Disease and premature death
- Eradicate unplanned admissions for Heart Failure - early diagnosis and treatment in the community, prevention of disease progression and hospitalisations
- Reduce death and progression to End Stage Renal Disease (ESRD) in Chronic Kidney Disease - early diagnosis and treatment, prevention of kidney function decline
- Eliminate Cancer as a cause of death - early diagnosis and biology-based treatments to revolutionise cancer care and increase the potential for cure
Join AstraZeneca
and help us deliver life-changing medicines
Be among our employees who continue to make us an innovation-driven company that stands firmly among the world’s leaders in biopharmaceuticals.
VVPM ID: GB-33550 Date of Prep: December 2021